文献速递妇科

上皮性卵巢癌每周紫杉醇治疗结局的生物标志物

Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2020-09-08

本研究旨在评估内在染色体畸变对上皮性卵巢癌(EOC)患者接受每周紫杉醇(WP)治疗结局的作用。在GENIUS研究(NCT03740503)中发现两例WP异常应答者共享8号染色体增益,随后在188例接受WP治疗的EOC患者中选取61例(39例短应答者、22例长应答者)进行浅全基因组测序验证,未发现8号染色体拷贝数改变或血管生成、微管蛋白超家族、细胞周期、凋亡及紫杉醇代谢/转运通路相关基因的差异改变。在长应答者中识别出6例超长应答者(应答持续超过一年),探索性分析显示超长应答者较短应答者血管生成基因(VEGFB、MMP9)、微管蛋白超家族基因(TSC2)及凋亡相关基因(BCL2L1、BAD)扩增增加。结论认为内在肿瘤通路可能影响每周紫杉醇单药治疗结局,需进一步研究。

要点

  • 两例WP异常应答者共享8号染色体增益。
  • 验证队列中8号染色体及候选通路基因拷贝数改变无差异。
  • 超长应答者血管生成、微管蛋白及凋亡基因扩增增加。

核心结论

  • 内在肿瘤通路可能影响每周紫杉醇单药治疗的结局,需进一步研究。

研究设计与样本

  • 评估GENIUS研究(NCT03740503)中两例对WP异常应答的EOC患者的常见基因组畸变。
  • 在验证队列中对188例接受WP治疗的EOC患者进行回顾,选取61例异常应答者(39例短应答者,22例长应答者)进行肿瘤组织浅全基因组测序(sWGS)。

主要发现

  • 两例WP异常应答持续超过四年,共享8号染色体增益。
  • 验证队列中8号染色体拷贝数改变无差异,血管生成、微管蛋白超家族、细胞周期、凋亡及紫杉醇代谢或转运通路相关基因的拷贝数改变也无差异。
  • 长应答者中识别出6例超长应答者,应答持续超过一年。
  • 探索性分析显示超长应答者较短应答者血管生成基因(VEGFB、MMP9)、微管蛋白超家族基因(TSC2)及凋亡相关基因(BCL2L1、BAD)扩增增加。
  • 一例患者对WP完全应答超过7年,分子谱分析识别出白细胞介素相关基因(CXCR1、CXCR2、IL1A、IL1B)独特扩增,其他患者未检测到。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We sought to evaluate the role of intrinsic chromosomal aberrations in determining favorable outcome to weekly paclitaxel (WP) in patients with epithelial ovarian cancer (EOC). METHODS: We evaluated the common genomic aberrations of two patients with EOC and exceptional WP response in the GENIUS study (NCT03740503). We then searched for potential markers of unusual outcomes to WP in a validation cohort. We performed shallow whole genome sequencing (sWGS) in the tumor tissue of women with EOC considered as short-responders (SR; progression with ≤3 cycles) and long-responders (LR; response at ≥8 cycles) to WP monotherapy. RESULTS: We identified two women with exceptional response to WP, lasting over four years, who shared chromosome 8 gain as a common genomic aberration. In order to validate our findings, we reviewed 188 patients with EOC treated with WP and selected 61 women (39 SR, 22 LR) with unusual responses. By sWGS, there was no differential alterations in the copy number changes in chromosome 8, or in genes related to angiogenesis, tubulin superfamily, cell-cycle, apoptosis and paclitaxel metabolism or transportation pathways. Amongst the LR group, we identified six exceptionally long responders (ExLR), with responses lasting over a year. In an exploratory analysis, there was increased amplification of angiogenesis (VEGFB, MMP9), tubulin superfamily (TSC2) and apoptosis related genes (BCL2L1, BAD) in ExLR compared to SR. We identified one patient with a complete response to WP for over 7 years. Molecular profiling identified unique amplifications in interleukin related genes (CXCR1, CXCR2, IL1A, IL1B), not detected in other patients. CONCLUSION: Intrinsic tumor pathways may impact outcome with weekly paclitaxel monotherapy and further investigations are required.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Madariaga A, Garg S, Bruce JP, et al. Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer. Gynecol Oncol. 2020. PMID: 32912664. doi:10.1016/j.ygyno.2020.08.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。